Analysis of results for the covered rate and acceptable performance of EQA items in nationwide medical laboratories from 2019 to 2023
10.13602/j.cnki.jcls.2025.02.10
- VernacularTitle:2019至2023年医学检验实验室室间质量评价项目参加率和合格率结果分析
- Author:
Zhixin ZHANG
1
;
Zhiguo WANG
;
Yuxuan DU
;
Bingquan CHEN
;
Wei WANG
Author Information
1. 北京医院国家老年医学中心 国家卫生健康委临床检验中心/北京市临床检验工程技术研究中心,中国医学科学院老年医学研究院,北京 100730
- Publication Type:Journal Article
- Keywords:
external quality assessment;
medical laboratory;
analyte
- From:
Chinese Journal of Clinical Laboratory Science
2025;43(2):126-129
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the status of medical laboratories participating in external quality assessment(EQA)program in China.Methods The test covered by an EQA control rate and acceptable performance rate of theinformation collection and data analy-sis systems in the EQA program developed by National Center for Clinical Laboratories in medical laboratories of nationwide various re-gions were evaluated descriptively and analyzed statistically.Forty analytes in various disciplines were selected to analyze statistically the implementation of the testing items and participation retes of EQA program.Results The number of medical laboratories participat-ing in EQA program increased yearly from 592 in 2019 to 1 169 in 2023.The nationwide median test covered by an EQA control rate and acceptable performance rate of EQA program reached over 91％and 98％,respectively.In 2023,the median test covered by an EQA control rate of EQA program in the medical laboratories of nationwide regions showed that the median test covered by an EQA con-trol rate reached 100％in Gansu and Hainan regions,and the medians of acceptable performance rate reached 100％in Beijing,Guangdong,Hubei,Jiangsu,Shandong,Shanxi,Shanghai,Tianjin,Xinjiang,and Zhejiang regions.Among the 40 analytes,the test covered by an EQA control rate of only 6 EQA items were greater than 80％in nationwide medical laboratories,i.e.,rheumatoid factor,neonatal deafness gene detection,high throughput sequencing of peripheral fetal chromosome aneuploidy(T21,T18 and T13)by high throughput sequencing,thalassemia gene typing,hepatitis C virus RNA quantification,and EGFR gene mutation,and the acceptable performance rates of only 3 EQA items were 100％,i.e.,HbA2,urine microalbumin,and non-invasive prenatal testing(NIPT).Thir-ty-six analytes exhibited acceptable performance rate above of 80％,while that of troponin I was below 80％.Conclusion The medical laboratories in China should further increase their test covered by an EQA control rate and acceptable performance rate of EQA pro-gram,and consistantly improve testing quality by utilizing EQA programs adequately.
